|drug742||Cellectra 2000 Electroporation Wiki||0.71|
|D020141||Hemostatic Disorders NIH||0.19|
|D001778||Blood Coagulation Disorders NIH||0.19|
|D011655||Pulmonary Embolism NIH||0.18|
There are 2 clinical trials
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012. Infection with MERS CoV has been diagnosed in more than 1600 individuals with a mortality rate between 35% and 40%. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This study will evaluate the safety of GLS-5300 at one of three dose levels following a three-injection vaccination regimen followed by electroporation. The study will also assess immune responses over a 1 year period with respect to the generation of antibody and cellular responses.
The Middle East Respiratory Syndrome Coronavirus (MERS CoV), is a cause of severe and highly fatal lower respiratory tract infection, first identified in 2012. As of August 2018, there have been 2229 cases reported with a case fatality rate >35%. In 2015 an individual returning to South Korea served as the index case for an outbreak of 186 individuals, of who, >20% died. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This Phase I/IIa study will evaluate the safety, tolerability and immunogenicity of GLS-5300 administered intradermally (ID) followed by electroporation at 0.3 and 0.6 mg/dose assessing 2 and 3-dose regimens.
Description: Incidence of Adverse events by System organ class (SOC); preferred term (PT); severity and relationship to study treatment and scheduleMeasure: Incidence of adverse events Time: Day0 through up to 60 weeks
Description: Administration (injection) site reactions described by frequencyMeasure: Administration (injection) site reactions Time: Day0 through up to 60 weeks
Description: Number of participants with changes based on frequency in safety lab parameters in Complete Blood Count and Liver panel tests" or similar.Measure: Changes in safety laboratory parameters Time: Day0 through up to 60 weeks
Description: Administration (injection) site pain as described by Visual Analog Scale (VAS)Measure: Administration (injection) site pain Time: Administration (injection) site pain
Description: Antigen specific cellular immune responses to MERS-CoV as determined by Interferon-gamma (IFN-γ) ELISpotMeasure: Cellular Immune Responses Time: Day0 through up to 60 weeks
Description: Binding antibody titers against MERS-CoV for a 2 and 3 dose vaccination regimensMeasure: Binding antibody titers Time: Day0 through up to 60 weeks
Description: Titers of neutralizing antibodies against MERS-CoVMeasure: Neutralizing antibodies Time: Day0 through up to 60 weeks
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports